Remote Senior Director, Payor And Health Systems Liaison, West

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor;
elironrasib (RMC-6291),a RAS(ON) G12C-selective inhibitor;
zoldonrasib (RMC-9805),a RAS(ON) G12D-selective inhibitor;
and RMC-5127, a RAS(ON)G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

Reporting to the Executive Director of Field Medical Affairs, the Payor and Health Systems Liaison will own and shape the scientific payer/access strategy for the ...